Paper Review Records
All Paper Review Records
24 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
296
days
Assessment of Pharmacokinetic Interaction and Clinical Efficacy of Clopidogrel Co‐administered with Ilaprazole
Authors
Damodharan N; Priyadharshini A; Vijayakumar T M; Rajesh N AShow moreShow less
Affiliations
1. Department of Pharmaceutics SRM College of Pharmacy SRM Institute of Science and Technology Kattankulathur Tamil Nadu India; 2. Department of Pharmacy Practice SRM College of Pharmacy SRM Institute of Science and Technology Kattankulathur Tamil Nadu India; 3. Department of Medical Gastroenterology SRM Medical College Hospital and Research Centre SRM Institute of Science and Technology Kattankulathur Tamil Nadu IndiaShow moreShow less
103
days
Bioequivalence Study of Two Ibuprofen Arginine Formulations in Healthy Chinese Subjects Under Fed Conditions
Authors
Yiyang Ying; Chunqi Huang; Li Xu; Yi Wu; Shufan Cai; Lijun Ye; Xiangxin Huang; Lin Wang; Ying WangShow moreShow less
Affiliations
1. The First Clinical Medical College Zhejiang Chinese Medical University Hangzhou Zhejiang Province China; 2. Department of Laboratory Medicine The Second Affiliated Hospital of Zhejiang Chinese Medical University, Xinhua Hospital of Zhejiang Province Hangzhou Zhejiang China; 3. School of Pharmacy Hangzhou Normal University Hangzhou Zhejiang China; 4. Clinical Research Center Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University Hangzhou China; 5. Zhejiang Key Laboratory of Zero Magnetic Medicine Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University Hangzhou ChinaShow moreShow less
214
days
Exposure–Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial
Authors
Mita Kuchimanchi; Trine Lembrecht Jørgensen; Eva Hanze; Angela Jain; Oskar Alskär; Oleksandr Zub; Mark S. Shahin; Anthoula Koliadi; Bhavana Pothuri; Thomas Krivak; Mikalai Pishchyk; Yakir Segev; Floor J. Backes; Christine Gennigens; Sara Bouberhan; Stefan Zajic; Murad Melhem; Joseph BuscemaShow moreShow less
Affiliations
1. GSK Waltham MA USA; 2. Department of Oncology Odense University Hospital Odense Denmark; 3. qPharmetra Uppsala Sweden; 4. Fox Chase Cancer Center Philadelphia PA USA; 5. Chernihiv Medical Center of Modern Oncology Chernihiv Regional Council Chernihiv Ukraine; 6. Division of Gynecologic Oncology Penn State Hershey Medical Center Hershey PA USA; 7. Department of Gynecologic Oncology Uppsala University Hospital Uppsala Sweden; 8. Nordic Society of Gynaecological Oncology (NSGO) Clinical Trial Unit Copenhagen Denmark; 9. Departments of Obstetrics and Gynecology and Medicine Division of Gynecologic Oncology NYU Langone Health New York NY USA; 10. GOG Foundation Philadelphia PA USA; 11. Division of Gynecologic Oncology The Western Pennsylvania Hospital Pittsburgh PA USA; 12. Grodno Regional Clinical Hospital Grodno Belarus; 13. Carmel Medical Center Technion‐Israel Institute of Technology Haifa Israel; 14. Division of Gynecologic Oncology Ohio State University Columbus OH USA; 15. Department of Medical Oncology CHU of Liège Liège Belgium; 16. Belgium and Luxembourg Gynaecological Oncology Group (BGOG) Leuven Belgium; 17. Massachusetts General Hospital Boston MA USA; 18. Affiliation at time of study GSK Collegeville PA USA; 19. TMC Healthcare Cancer Center Tucson AZ USAShow moreShow less
88
days
Open‐Label, Balanced, Randomized, Single‐Dose, Three‐Treatment, Three‐Sequence, Three‐Period, Three‐Way Crossover Oral Bioequivalence Study of Desmopressin Acetate Oral Solution
Authors
Adam Christensen; Axay Parth; Mansi Kotak; Danka Radosavjevic; Catherine Gorman Moore; Byung‐Woun SeoShow moreShow less
Affiliations
1. Eton Pharmaceuticals Deer Park IL USA; 2. Veeda Clinical Research, Mehsana Panchot India; 3. Veeda Clinical Research Ahmedabad Gujarat IndiaShow moreShow less
87
days
Safety, Tolerability, Pharmacokinetics, Food Effect of Ribitol, and Its Effect on QTcF in Healthy Adults: First‐in‐Human, Randomized, Double‐Blind (Sponsor Unblinded), Placebo‐Controlled Studies
Authors
Daniel D. Gretler; Athiwat Hutchaleelaha; Uma Sinha; Kristen Rickert; Doug SprouleShow moreShow less
Affiliations
1. Bridgebio Pharma, Inc. Palo Alto CA USAShow moreShow less
55
days
Phase 1 Study of Paltusotine, a Novel Oral Once‑Daily, Nonpeptide Selective Somatostatin Receptor 2 Agonist, in Healthy Japanese Adults
Authors
Fumio Otsuka; Keiko Hanabara; Seigo Akari; Katsunori Kitamoto; Yosuke Inagaki; Dylan Glatt; Harumi Murakami; Naoki UchidaShow moreShow less
Affiliations
1. Department of General Medicine Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan; 2. Medical Affairs Group Medical Affairs Department Sanwa Kagaku Kenkyusho Co., Ltd. Nagoya Japan; 3. Project Management Group Project Management Department Sanwa Kagaku Kenkyusho Co., Ltd. Nagoya Japan; 4. Clinical Development Department Sanwa Kagaku Kenkyusho Co., Ltd. Nagoya Japan; 5. Crinetics Pharmaceuticals, Inc. San Diego USA; 6. Souseikai Sumida Hospital Tokyo Japan; 7. Division of Clinical Pharmacology Department of Pharmacology Showa Medical University School of Medicine Tokyo JapanShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days